Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid

Sports Medicine

Volumn 32, Issue 2, 2002, Pages 125-142

  Wilber, Randall L ^a  

^a United States Olympic Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR;

ANALYTIC METHOD; ATHLETE; BLOOD SAMPLING; DNA RECOMBINATION; DOPING; ELECTROPHORETIC MOBILITY; ENDURANCE; ERYTHROPOIESIS; EXERCISE; HEMATOCRIT; HUMAN; ISOELECTRIC FOCUSING; OXYGEN CONSUMPTION; RETICULOCYTE COUNT; REVIEW;

EID: 0036175031     PISSN: 01121642     EISSN: None     Source Type: Journal    
DOI: 10.2165/00007256-200232020-00004     Document Type: Review

References (98)

1. Detection of autologous blood transfusions in cross-country skiers
2. Blood transfusion and athletics
3. Evaluation of prevalence of doping among Italian athletes
4. Changes in hemoglobin values in elite cross-country skiers from 1987 to 1999
5. Olympic cheating: The inside story of illicit doping and the U.S. cycling team
6. Banned drugs in sport
7. Seeking an edge, cheating US skier places Nordic world on edge
8. A sport in shame
9. Stamina-building drug linked to athletes' deaths
10. Drug scandal shakes cycling
11. The tour in peril
12. Drug pedaling
13. International Olympic Committee Medical Commission prohibited classes of substances and methods of doping, 2000 Feb 15
14. The use of blood doping as an ergogenic aid
15. Effects of blood transfusions on some hematological variables in endurance athletes
16. Effect of reinfusion of autologous blood on exercise performance in cross-country skiers
17. Effect of induced erythrocythemia on aerobic work capacity
18. Effects of anemia and stepwise-induced polycythemia on maximal aerobic power in individuals with high and low haemoglobin concentrations
19. Response to exercise after blood loss and reinfusion
20. Central circulation during exercise after venesection and reinfusion of red blood cells
21. Blood doping and related issues: A brief review
22. The influence of altered blood volume and oxygen transport capacity on aerobic performance
23. Haemoglobin, blood volume, cardiac function, and aerobic power
24. Effect of induced erythrocythemia on hypoxia tolerance during physical exercise
25. Hemoglobin concentration and aerobic work capacity in women following induced erythrocythemia
26. Influence of polycythemia on blood volume and thermoregulation during exercise-heat stress
27. Erythrocyte infusion and maximal aerobic power: An examination of modifying factors
28. The effects of induced erythrocythemia on central circulation and oxygen transport during maximal exercise
29. Effect of graded erythrocythemia on cardiovascular and metabolic responses to exercise
30. Oxygen transport during exercise following blood reinfusion
31. Effect of blood reinjection upon endurance capacity and heart rate
32. The effect of blood infusion upon endurance capacity and ratings of perceived exertion
33. The effect of induced erythrocythemia upon 5-mile treadmill run time
34. The increase in hypoxia tolerance of normal men accompanying the polycythemia induced by transfusion of erythrocytes
35. Recombinant erythropoietin to improve athletic performance
36. The abuse of erythropoietin to enhance athletic performance
37. rHuEPO: Sport's newest drug threat
38. All doped up and going for the gold
39. Use of recombinant human erythropoietin outside the setting of uremia
40. Induced erythrocythemia and athletic performance
41. Performance-enhancing drugs, fair competition, and Olympic sport
42. Physiology of erythropoietin production
43. The molecular mechanism of erythropoietin action
44. Polycythemic responses to hypoxia: Molecular and genetic mechanisms of chronic mountain sickness
45. Control of erythropoiesis in humans during prolonged exposure to the altitude of 6,542 m
46. Ergogenic aids
47. Morphology of the erythron
48. Biology of erythropoietin
49. Epoetin alfa
50. Pharmacokinetics and erythropoietic response to human erythropoietin in healthy men
51. Diurnal variations of serum erythropoietin in trained and untrained subjects
52. Diurnal variations of serum erythropoietin at sea level and altitude
53. Erythropoietin does not demonstrate circadian rhythm in healthy men
54. Effects of acute exercise on plasma erythropoietin levels in trained runners
55. Exercise duration and serum erythropoietin level
56. Transferrin soluble receptor: A possible probe for detection of erythropoietin abuse by athletes
57. Evaluation of erythropoietin in endurance runners
58. Effect of maximal and submaximal exercise under normoxic and hypoxic conditions on serum erythropoietin level
59. Erythropoietic adaptations to endurance training
60. Serum erythropoietin in athletes at moderate altitude
61. Serum erythropoietin in cross-country skiers
62. Application of a modified INCSTAR Epo-Trac 125/RIA for measurement of serum erythropoietin concentration in elite athletes
63. Lethal injection
64. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined Phase I and II clinical trial
65. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers
66. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers
67. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration of healthy subjects
68. Adverse events of erythropoietin in long-term and in acute/short-term treatment
69. Recombinant erythropoietin
70. A global strategy for prevention and detection of blood doping with erythropoietin and related drugs
71. Rapid method for detection of anti-recombinant human erythropoietin antibodies as a new form of erythropoietin resistance
72. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in athletes. Blood sampling and doping control
73. Erythropoietin (rHuEPO) doping: Effects of exercise on anaerobic metabolism in rats
74. The effect of recombinant human erythropoietin treatment on the endurance performance of Sprague-Dawley rats
75. Long term cardiorespiratory effects of amelioration of renal anemia by erythropoietin
76. Working capacity is increased following recombinant human erythropoietin treatment
77. Improvement in exercise capacity after correction of anemia in patients with endstage renal failure
78. Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients
79. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control
80. Enhanced oxygen availability during high intensity intermittent exercise decreases anaerobic metabolite concentrations in blood
81. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men
82. Effect of rhEPO administration on serum levels of sTfR and cycling performance
83. Blood doping and erythropoietin
84. Effects of erythropoietin administration on maximal aerobic power
85. The future of doping control in athletes
86. Hematological indices of erythropoietin administration in athletes
87. Population pharmacodynamics for monitoring epoetin in athletes
88. Erythropoietin abuse in athletes
89. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis
90. Detection in blood and urine of recombinant erythropoietin administered to healthy men
91. Recombinant erythropoietin in urine
92. The ethics of blood testing as an element of doping control in sport
93. Investigation of the rhEPO detection protocol in athletes sojourning to the Salt Lake City Olympic cross-country venue